Skip to main content

Table 2 Breast cancer mortality risk by hormone receptor status among women of different diagnosis age, race/ethnicity, diagnosis year, tumor stage, grade, histology, and axillary lymph node positivitya

From: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

 

ER+/PR+

ER+/PR-

ER-/PR+

ER-/PR-

 
 

(n = 98,463)

(n = 19,886)

(n = 4,896)

(n = 31,930)

 

Characteristics

No. at risk

No. deaths

HR

No. at risk

No. deaths

HR

95% CI

No. at risk

No. deaths

HR

95% CI

No. at risk

No. deaths

HR

95% CI

p value for interaction

All casesb

98,463

7,319

1.0

19,886

2,434

1.4

1.3–1.5c

4,896

848

1.8

1.6–1.9c

31,930

6,300

2.3

2.2–2.4c

 

Age at diagnosis, yearsd

                

   <50

16,962

1,042

1.0

2,387

245

1.2

1.1–1.4c

1,430

209

1.6

1.4–1.9c

8,056

1,323

2.1

1.9–2.3c

 

   50–64

23,467

1,104

1.0

4,745

416

1.5

1.3–1.7c

1,072

124

1.5

1.2–1.8c

7,651

1,214

2.3

2.1–2.5c

 

   ≥65

25,078

1,496

1.0

5,563

540

1.5

1.3–1.7c

718

119

2.1

1.8–2.6c

5,536

1,020

2.6

2.4–2.8c

0.03

Diagnosis yeare

                

   1990–1992

8,298

1,285

1.0

1,889

419

1.3

1.2–1.5c

597

146

1.6

1.3–1.9c

2,850

831

1.7

1.5–1.9c

 

   1993–1995

13,665

1,348

1.0

2,688

428

1.5

1.3–1.7c

944

160

1.5

1.2–1.8c

4,859

1,234

2.2

2.0–2.4c

 

   1996–1998

19,350

837

1.0

3,493

282

1.5

1.3–1.7c

971

121

2.1

1.7–2.6c

6,181

1,059

2.8

2.5–3.1c

 

   1999–2001

24,194

172

1.0

4,625

69

1.6

1.2–2.1c

708

25

3.6

2.3–5.1c

7,353

433

4.9

4.1–6.0c

<0.001

Race/Ethnicityf

                

   Non-Hispanic white

53,397

2,831

1.0

10,187

916

1.5

1.3–1.6c

2,396

313

1.8

1.6–2.0c

15,371

2,462

2.3

2.2–2.5c

 

   African-American

3,536

348

1.0

907

125

1.2

1.0–1.5c

293

60

1.7

1.3–2.2c

2,734

615

2.2

1.9–2.6c

 

   Native American

196

19

1.0

34

11

1.5

0.5–3.8

12

1

1.7

0.1–16.4

102

25

3.4

1.5–7.3c

 

   Asian/Pacific Islander

4,497

189

1.0

748

63

1.8

1.3–2.4c

267

34

1.6

1.1–2.4c

1,273

166

2.3

1.8–2.8c

 

   Hispanic white

3,881

255

1.0

819

83

1.3

1.0–1.7c

252

44

1.9

1.3–2.6c

1,763

289

2.3

1.9–2.8c

0.77

Tumor stageg

                

   I

33,821

487

1.0

6,038

146

1.4

1.2–1.7c

1,369

51

1.6

1.2–2.1c

7,704

391

2.3

2.0–2.7c

 

   II

27,363

2,110

1.0

5,472

674

1.4

1.3–1.6c

1,529

248

1.6

1.4–1.9c

11,051

2,069

2.3

2.2–2.5c

 

   III

3,410

659

1.0

922

252

1.3

1.2–1.6c

245

104

2.1

1.7–2.6c

1,940

763

2.3

2.0–2.6c

 

   IV

672

302

1.0

192

102

1.3

1.0–1.6c

59

42

1.9

1.3–2.7c

357

245

2.3

1.9–2.8c

0.45

Tumor size (cm)h

                

   0–1.9

39,418

865

1.0

6,957

243

1.4

1.2–1.6c

1,607

91

1.5

1.2–1.9c

8,799

715

2.6

2.3–2.9c

 

   2–5

22,579

2,081

1.0

4,781

708

1.5

1.3–1.6c

1,331

253

1.8

1.5–2.0c

10,214

2,019

2.2

2.1–2.4c

 

   >5

2,718

526

1.0

761

206

1.3

1.1–1.6c

217

89

2.2

1.7–2.7c

1,730

636

2.2

1.9–2.5c

<0.001

Axillary lymph node statusi

                

   Negative

42,451

942

1.0

7,924

324

1.6

1.4–1.8c

1,898

114

2.0

1.6–2.4c

12,541

1,006

2.8

2.6–3.1c

 

   1–3

14,953

1,021

1.0

2,828

324

1.5

1.3–1.7c

790

133

1.8

1.5–2.1c

4,857

977

2.5

2.3–2.7c

 

   4–10

5,313

861

1.0

1,133

277

1.4

1.2–1.6c

332

108

1.7

1.3–2.1c

2,268

793

2.4

2.2–2.7c

 

   ≥11

2,549

734

1.0

739

249

1.2

1.0–1.4c

182

90

1.7

1.3–2.1c

1,386

692

2.2

1.9–2.4c

0.08

Tumor histologyj

                

   Ductal

52,178

2,919

1.0

9,978

994

1.5

1.4–1.6c

2,711

390

1.8

1.6–2.0c

18,542

3,040

2.3

2.2–2.5c

 

   Lobular

3,975

186

1.0

938

64

1.4

1.0–1.9c

123

3

0.4

0.1–1.4

325

47

1.9

1.4–2.7c

 

   Ductal/Lobular

5,472

254

1.0

929

59

1.3

0.9–1.7

148

13

1.1

0.6–2.0

511

83

2.7

2.1–3.5c

 

   Inflammatory

241

52

1.0

77

22

1.4

0.8–2.3

39

19

3.4

1.9–6.1c

258

123

3.5

2.4–5.0c

 

   Comedo

652

91

1.0

187

19

0.6

0.4–1.1

91

16

1.2

0.7–2.1

556

109

1.6

1.2–2.1c

 

   Medullary

120

14

1.0

73

6

0.7

0.2–2.2

48

4

0.9

0.2–3.0

716

54

0.7

0.4–1.4

<0.001

Tumor gradek

                

   1

13,854

156

1.0

2,141

40

1.6

1.1–2.3c

310

6

1.0

0.4–2.5

661

32

2.6

1.7–3.9c

 

   2

32,661

1,349

1.0

5,555

374

1.5

1.3–2.1c

1,074

95

1.7

1.3–2.1c

4,312

575

3.1

2.8–3.4c

 

   3

17,352

1,873

1.0

4,613

710

1.3

1.2–1.5c

1,694

319

1.7

1.5–1.9c

14,967

2,635

2.1

1.9–2.2c

 

   4

1,399

180

1.0

315

50

1.4

1.0–2.0c

124

25

2.1

1.4–3.3c

1,112

226

2.3

1.8–2.8c

<0.001

  1. aThe reference ER/PR profile for all analyses was ER+/PR+. bHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). c p < 0.05. dHRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). eHRs adjusted for age at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). fHRs adjusted for age and year at diagnosis, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). Race unknown, n = 3,185. gHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status (categorical), and surgical and radiation treatment. Stage unknown, n = 4,728. hHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status (categorical), and surgical and radiation treatment. Size unknown, n = 7,196. iHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, grade, and surgical and radiation treatment. Nodal status unknown, n = 22,394. jHRs adjusted for age and year at diagnosis, race, SEER registry, tumor grade, stage, lymph node status (categorical), and surgical and radiation treatment. Other/unknown histology, n = 7,155. kHRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, lymph node status (categorical), and surgical and radiation treatment. Grade unknown, n = 24,544. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.